SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Parabilis Medicines, Inc. (PBLS) News

Follow Parabilis Medicines, Inc. (PBLS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol PBLS Asset equity Sector Markets 90 days 6 Last 27.53 Updated Oct 24, 2026, 12:47 PM UTC Open live news feed Open PBLS chart & news
M Parabilis Reports 72.2% ORR in Zolucatetide Study; FDA Aligns on Phase 3 Parabilis reported a 72.2% objective response rate (13/18) at doses of at least 450 mg in a 32-week Phase 1/2 analysis of zolucatetide in desmoid tumors. The company said the FDA aligned on dose, placebo-controlled desig EQUITY | Oct 24, 2026, 12:47 PM UTC L Parabilis Medicines begins zolucatetide study in familial adenomatous polyposis Parabilis Medicines initiated a dose-ranging clinical study of zolucatetide in familial adenomatous polyposis. EQUITY | Oct 14, 2026, 11:00 AM UTC L Parabilis Chief Medical Officer to leave effective Sept. 30, 2026 Parabilis said Fawzi Benzaghou, M.D. will transition from his role as chief medical officer effective Sept. 30, 2026. REGULATION | Sep 02, 2026, 08:13 PM UTC L Parabilis Medicines to participate in Morgan Stanley 24th healthcare conference Parabilis Medicines says its Chairman and President will participate in the Morgan Stanley 24th Annual Global Healthcare Conference. EQUITY | Sep 01, 2026, 11:08 AM UTC L Parabilis Medicines to participate in Morgan Stanley healthcare conference Parabilis Medicines plans to participate in the Morgan Stanley 24th Annual Global Healthcare Conference. EQUITY | Sep 01, 2026, 11:00 AM UTC L Parabilis Medicines appoints Dr. Craig L. Tendler to board Parabilis Medicines (PBLS) appoints drug development leader Craig L. Tendler, M.D., to its board of directors. EQUITY | Aug 25, 2026, 11:00 AM UTC L Parabilis Medicines reports Q2 2026 financial results, business updates Parabilis Medicines (PBLS) reports its second-quarter 2026 financial results and provides accompanying business updates. EARNINGS | Aug 13, 2026, 11:01 AM UTC L This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Evercore ISI Grou EQUITY | Jul 06, 2026, 11:11 AM UTC L Buy Recommendation Issued On PBLS By Guggenheim 2026-07-06 03:15:02 ET Guggenheim analyst issues BUY recommendation for PBLS on July 6, 2026 06:39AM ET. < EQUITY | Jul 06, 2026, 07:15 AM UTC